Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Invasive aspergillosis in cancer patients
Autore:
Bow, EJ;
Indirizzi:
Univ Manitoba, Dept Internal Med, Winnipeg, MB R3T 2N2, Canada Univ Manitoba Winnipeg MB Canada R3T 2N2 ed, Winnipeg, MB R3T 2N2, Canada Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3T 2N2, Canada Univ Manitoba Winnipeg MB Canada R3T 2N2 ol, Winnipeg, MB R3T 2N2, Canada Univ Manitoba, Hematol Oncol Sect, Winnipeg, MB R3T 2N2, Canada Univ Manitoba Winnipeg MB Canada R3T 2N2 ct, Winnipeg, MB R3T 2N2, Canada Canc Care Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada Canc Care Manitoba Winnipeg MB Canada ol & Hematol, Winnipeg, MB, Canada Canc Care Manitoba, Infect Control Serv, Winnipeg, MB, Canada Canc Care Manitoba Winnipeg MB Canada Control Serv, Winnipeg, MB, Canada
Titolo Testata:
ONCOLOGY-NEW YORK
fascicolo: 8, volume: 15, anno: 2001,
pagine: 1035 - 1039
SICI:
0890-9091(200108)15:8<1035:IAICP>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
MARROW TRANSPLANT RECIPIENTS; LAMINAR AIR-FLOW; FUNGAL-INFECTIONS; AMPHOTERICIN-B; ACUTE-LEUKEMIA; PROPHYLACTIC ANTIBIOTICS; PULMONARY ASPERGILLOSIS; PROTECTED ENVIRONMENT; ITRACONAZOLE THERAPY; NEUTROPENIC PATIENTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Bow, EJ Hlth Sci Ctr, Dept Med, Infect Dis Sect, Room GD600,820 Sherbrook St, Winnipeg, MB, Canada Hlth Sci Ctr Room GD600,820 Sherbrook St Winnipeg MB Canada anada
Citazione:
E.J. Bow, "Invasive aspergillosis in cancer patients", ONCOLOGY-NY, 15(8), 2001, pp. 1035-1039

Abstract

The incidence of invasive aspergillosis is increasing parallel to the intensity of immunosuppressive and myelosuppressive anticancer treatments. Successful management is linked to an understanding of the pathogenesis and recognition of risk factors. Identifying the patients and clinical circumstances associated with the highest risk for invasive aspergillosis and managingpatients in protected environments remain the most effective means of prevention. Early accurate diagnosis continues to be a challenge; however, newer non-culture-based methods are encouraging and have been incorporated intostandardized case definitions. Unacceptably high mortality rates persist with current treatment of established infection. Among the newer potentiallyless toxic antifungal therapies are the triazoles, and lipid-based polyene-formulations that target the fungal cell membrane and 1,3-beta-D-glitcan synthase inhibitors that target the fungal cell wall. These agents are currently in clinical trials. Host defense augmentation using hematopoietic growth factors with or without other cytokines such as interferon-gamma or hematopoietic growth factor-stimulated neutrophil transfusions remain controversial strategies that have yet to be tested in well-designed randomized controlled trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 22:52:55